Hologic Reports Better-Than-Expected Q1 Results

by Erica Kollmann Benzinga Staff Writer

Zinger Key Points

Hologic reports quarterly adjusted earnings of 98 cents per share, beating the analyst consensus estimate of 95 cents by 3.16%.
Hologic reports quarterly sales of $1.01 billion, beating the analyst consensus estimate of $986.12 million by 2.73%.
Get 5 stock picks identified before their biggest breakouts, identified by the same system that spotted Insmed, Sprouts, and Uber before their 20%+ gains.

Hologic, Inc. HOLX reported better-than-expected first-quarter financial results after the bell Thursday. Here's a look at the highlights.

The Details: Hologic reported quarterly adjusted earnings of 98 cents per share, beating the analyst consensus estimate of 95 cents by 3.16% and representing an 8.41% decrease over earnings of $1.07 per share from the same period last year.

Quarterly sales clocked in at $1.01 billion, beating the analyst consensus estimate of $986.12 million by 2.73% and representing a 5.68% decrease over sales of $1.07 billion year-over-year.

Hologic saw second-quarter revenue of between $990 million and $1.01 billion and earnings of between 95 cents and $1.00 per share.

"We delivered strong revenue and profitability to start fiscal 2024, exceeding the high-end of our guidance for both the top-line and the bottom-line. Adjusting for the four fewer selling days in the quarter, we estimate our organic growth rate ex. COVID-19 was in the high single digits, highlighting the bigger, faster, stronger Hologic we are today," said Stephen P. MacMillan, CEO of Hologic.

HOLX Price Action: According to Benzinga Pro, Hologic shares are trading down 0.15% after-hours at $74.30 at the time of publication Thursday.

Photo: Courtesy Hologic

HOLXHologic Inc

$63.90-0.71%

Overview

Market News and Data brought to you by Benzinga APIs